EP300 and cancer: Suppression of histone acetylation by the p300/CBP enzymes is an emerging strategy for cancer therapy (Yang et al., 2013; Gu et al., 2016; Lasko et al., 2017; Wang et al., 2017; van Gils et al., 2021).